Document Detail


Management of female-to-male transgender persons: medical and surgical management, life expectancy.
MedLine Citation:
PMID:  24755998     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Hormonal treatment of transgender people is becoming a normal part of medicine, though numbers of subjects remain small because of low prevalence. Information on treatment is scattered and this review brings together the latest information on treatment goals and potential side-effects of androgen treatment of female-to-male transsexual subjects.
RECENT FINDINGS: Androgen treatment of female-to-male transsexuals is usually uneventful, with a good patient compliance. Goals of hormonal treatment are elimination of secondary sex characteristics of the female sex and induction of those of the male sex. Completion takes approximately 2 years. Hormonal treatment is eventually followed by surgical ablation of breasts and removal of uterus and ovaries. Phalloplasty may be considered. Concerns are the sequelae of hypogonadism following surgery, such as loss of bone mass. Contrary to earlier expectations, there is no increase in cardiovascular disease. (Hormone-related) cancers are rare, but vaginal, cervical, endometrial carcinomas have been reported. Cancers of the breasts are of greater concern and have been found in residual mammary tissue after breast ablation. So far, androgen treatment has not raised major safety concerns. Regrets about changing sex have not been reported.
SUMMARY: Testosterone treatment of female-to-male transsexuals is effective and well tolerated.
Authors:
Louis J Gooren
Related Documents :
6895838 - Intralaboratory variations in the grading of breast carcinoma.
24859938 - Characterization and treatment of local recurrence following breast conservation for du...
12189508 - Prognostic impact of metallothionein on oral squamous cell carcinoma.
8142628 - Clinical significance of cellular dna ploidy in rectal cancer less than 3 cm in diameter.
12715638 - Incidence of bony secondary at presentation of breast carcinoma in our region.
11172288 - Expression of cell-cycle-associated proteins prb2/p130 and p27kip in vulvar squamous ce...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in endocrinology, diabetes, and obesity     Volume:  21     ISSN:  1752-2978     ISO Abbreviation:  Curr Opin Endocrinol Diabetes Obes     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-04-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101308636     Medline TA:  Curr Opin Endocrinol Diabetes Obes     Country:  England    
Other Details:
Languages:  eng     Pagination:  233-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current and emerging therapies for Addison's disease.
Next Document:  Developmental changes in mismatch responses to mandarin consonants and lexical tones from early to m...